Revenue recognition is one of the most technically demanding areas of accounting for any company. In biotech and life sciences, it is particularly complex. The combination of upfront license fees, development milestones, regulatory approval payments, and royalty streams creates arrangements that require careful analysis under current accounting standards. Getting this right matters enormously, not just for compliance, but for how your business looks to investors, acquirers, and auditors. 

This post breaks down how ASC 606, the current U.S. GAAP revenue recognition standard, applies to milestone-based license agreements in biotech, and what your company should be doing to ensure its financials accurately reflect the economics of these arrangements. 

The ASC 606 Framework in Plain Terms 

ASC 606, which became effective for private companies for fiscal years beginning after December 15, 2018, introduced a unified five-step model for revenue recognition that applies across industries and business models. The five steps are: identify the contract, identify the performance obligations within it, determine the transaction price, allocate the transaction price to the performance obligations, and recognize revenue when or as each performance obligation is satisfied. 

For straightforward businesses, this model is relatively easy to apply. For biotech companies with complex licensing arrangements, nearly every step requires significant judgment, and the choices made at each step can have major consequences for reported revenue and the timing of its recognition. 

Identifying Performance Obligations in Licensing Arrangements 

One of the first challenges in a biotech licensing arrangement is determining how many distinct performance obligations exist within the contract. A license agreement might include the transfer of intellectual property rights, ongoing research and development services, manufacturing obligations, data-sharing commitments, and participation on joint steering committees. Each of these could be a separate performance obligation, or several could be combined into a single obligation, depending on whether they are truly distinct from one another in both function and context. 

Under ASC 606, a good or service is distinct if the customer can benefit from it on its own (or together with other resources that are readily available to the customer) and if the entity’s promise to transfer it is separately identifiable from other promises in the contract. For an early-stage biotech company transferring a license along with significant ongoing research and development support, the license and the R&D services may not be distinct from one another. This means they would be treated as a combined performance obligation, and revenue from the entire arrangement would be recognized over the period during which the R&D performance occurs, rather than upfront at the time the license is granted. 

This single determination can have a profound impact on when a company recognizes revenue from a deal that might be worth tens or hundreds of millions of dollars. A licensing arrangement that an executive team describes as generating $20 million in upfront revenue may, under ASC 606, produce far less recognized revenue in the current period once the performance obligation analysis is complete. 

Handling Milestone Payments: The Variable Consideration Challenge 

Development milestones are a defining feature of most biotech licensing arrangements. A licensee might agree to pay the licensor upon the achievement of specific clinical or regulatory events: successful completion of a Phase 1 or Phase 2 trial, submission of a New Drug Application, receipt of FDA approval, or first commercial sale in a designated territory. These payments are almost always classified as variable consideration under ASC 606 because their receipt depends on future events that may or may not occur. 

Variable consideration must be estimated and included in the transaction price, but only to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty around the variable amount is ultimately resolved. This is known as the constraint on variable consideration, and it requires significant judgment on the part of the preparer. 

For many development milestones, particularly those tied to late-stage clinical outcomes or regulatory decisions, the constraint means that the milestone amount is excluded from the transaction price entirely until the triggering event either occurs or becomes highly probable of occurring. A Phase 3 trial completion milestone, for example, may need to be excluded from recognized revenue until the trial data is in hand and the outcome is clear, regardless of how optimistic management may be about the probability of success. 

According to the FASB’s implementation guidance and feedback from the life sciences industry, this is one of the most frequently misapplied aspects of ASC 606 in the biotech context. Companies that recognize milestone revenue based on management’s internal probability assessments, rather than the formal constraint analysis required by the standard, expose themselves to audit adjustments and potential restatements. 

Sales-Based and Usage-Based Royalties: A Special Case 

ASC 606 includes a specific exception for sales-based and usage-based royalties on licenses of intellectual property. Under this exception, royalty revenue is recognized only when the subsequent sale or usage by the licensee actually occurs, and not before, regardless of when or how the related performance obligation was satisfied. 

This exception applies even when the royalty relates to a license that has already been fully transferred and all other performance obligations have been satisfied. For many biotech licensors, this means that royalty streams, even economically significant ones tied to successful commercialization, will not appear in reported revenue until the underlying commercial activity occurs and is reported by the licensee. 

Companies that have out-licensed products with commercial potential and are anticipating royalty income need to understand this rule clearly when communicating financial results and forward projections to investors, lenders, and board members. 

Upfront Fees and When They Can Be Recognized 

Nonrefundable upfront payments received in exchange for a license are another area requiring careful analysis. If the license is determined to be distinct and represents functional intellectual property (meaning it has standalone value and does not change substantially over the license period as a result of the licensor’s ongoing activities), the upfront fee may be recognized at the point in time when the license is transferred. 

However, if the license is not distinct from ongoing development or manufacturing services, the upfront payment is generally deferred and recognized over the combined performance period. Given that early-stage biotech licenses often come with significant ongoing obligations on the part of the licensor, upfront fees are frequently spread over an extended period rather than recognized immediately. 

The assumptions underlying this allocation, including the estimated length of the performance period, must be disclosed and are subject to revision if facts and circumstances change. Changes in estimated performance periods can affect multiple reporting periods and create volatility in reported revenue that may require explanation to investors. 

Why Accurate Revenue Recognition Matters Beyond Compliance 

Accurate revenue recognition under ASC 606 affects more than just the income statement. It directly influences your reported gross margin, your EBITDA, and the financial metrics your investors and board use to evaluate performance and company value. In a sector where many companies are pre-revenue or early-revenue and valuations are often based on pipeline milestones rather than earnings, the way revenue is recognized and the assumptions that underlie that recognition can be a significant area of scrutiny in fundraising due diligence. 

Life sciences companies approaching their Series B or Series C, or those beginning discussions with potential strategic partners or acquirers, frequently discover during the due diligence process that their historical revenue recognition does not hold up under close examination. Correcting these issues under time pressure, in the middle of a deal process, is far more disruptive and costly than addressing them in advance. 

According to Audit Analytics, revenue-related adjustments and restatements remain among the most common categories of financial restatement across all industries, and life sciences companies are disproportionately represented in that data. The complexity of milestone and royalty arrangements is a primary driver. 

For companies working toward their first formal audit, planning a fundraising round, or entering into a significant licensing transaction, having clean, defensible revenue recognition policies in place is not optional. Escalon’s financial operations team works with life sciences companies to build revenue recognition frameworks that reflect both the technical requirements of ASC 606 and the commercial realities of their specific business model. 

Building the Right Foundation Early 

The good news is that getting revenue recognition right in biotech does not require resolving every possible edge case before signing your first licensing deal. It does require having accounting professionals involved in the process before the deal closes, not after, and establishing clear documentation for the judgments made in each of the five steps of the ASC 606 analysis. 

This documentation matters for two reasons. First, it supports your audit. Auditors reviewing a biotech company’s revenue recognition need to understand the basis for management’s conclusions, and well-documented contemporaneous analysis is far more defensible than a reconstruction prepared months after the fact. Second, it creates institutional knowledge that makes future arrangements easier to analyze and price appropriately. 

For biotech companies building their accounting infrastructure from the ground up, Escalon’s fractional CFO services provide the senior-level financial expertise to navigate complex revenue accounting questions alongside the operational infrastructure to maintain clean books and records on an ongoing basis. 

If your biotech company is navigating complex licensing arrangements and you are not fully confident in how your revenue is being recognized, the time to address that is before your next audit or your next fundraise, not during it. 

Contact Escalon today to learn how we support life sciences companies in building compliant, auditor-ready revenue recognition policies from the ground up.